CN102481345B - 精氨酸酶的定向位点聚乙二醇化及其作为抗癌和抗病毒试剂的用途 - Google Patents

精氨酸酶的定向位点聚乙二醇化及其作为抗癌和抗病毒试剂的用途 Download PDF

Info

Publication number
CN102481345B
CN102481345B CN201080023256.4A CN201080023256A CN102481345B CN 102481345 B CN102481345 B CN 102481345B CN 201080023256 A CN201080023256 A CN 201080023256A CN 102481345 B CN102481345 B CN 102481345B
Authority
CN
China
Prior art keywords
arginase
peg
enzyme
human
bacillus cereus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080023256.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102481345A (zh
Inventor
梁润松
劳伟雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong Kong Polytechnic University
Original Assignee
Hong Kong Polytechnic University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Kong Polytechnic University filed Critical Hong Kong Polytechnic University
Publication of CN102481345A publication Critical patent/CN102481345A/zh
Application granted granted Critical
Publication of CN102481345B publication Critical patent/CN102481345B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201080023256.4A 2009-03-26 2010-03-26 精氨酸酶的定向位点聚乙二醇化及其作为抗癌和抗病毒试剂的用途 Active CN102481345B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16386309P 2009-03-26 2009-03-26
US61/163,863 2009-03-26
PCT/CN2010/071357 WO2010124547A1 (en) 2009-03-26 2010-03-26 Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents

Publications (2)

Publication Number Publication Date
CN102481345A CN102481345A (zh) 2012-05-30
CN102481345B true CN102481345B (zh) 2015-04-22

Family

ID=42784510

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080023256.4A Active CN102481345B (zh) 2009-03-26 2010-03-26 精氨酸酶的定向位点聚乙二醇化及其作为抗癌和抗病毒试剂的用途

Country Status (7)

Country Link
US (1) US8507245B2 (enExample)
EP (1) EP2411040B1 (enExample)
JP (1) JP5746137B2 (enExample)
CN (1) CN102481345B (enExample)
AU (1) AU2010242422B2 (enExample)
CA (1) CA2756442C (enExample)
WO (1) WO2010124547A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382525B2 (en) * 2009-03-26 2016-07-05 The Hong Kong Polytechnic University Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
CA2766039A1 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
JP6063378B2 (ja) 2010-01-26 2017-01-18 バンヤン・バイオマーカーズ・インコーポレイテッド アルギニノコハク酸合成酵素に関係する組成物および方法
EP2654776B1 (en) * 2010-12-21 2018-11-21 Bio-Cancer Treatment International Ltd. Use of pegylated recombinant human arginase for treatment of leukemia
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
US8877183B2 (en) 2012-06-26 2014-11-04 National Institutes Of Health (Nih) Methods for treatment of ocular diseases
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
EP3137103B1 (en) 2014-04-29 2021-10-20 Bio-Cancer Treatment International Ltd. Methods and compositions for modulating the immune system with arginase i
CN105112391B (zh) * 2015-09-22 2018-07-06 浙江道尔生物科技有限公司 一种人源精氨酸酶突变体及其制备方法和用途
CN106692961B (zh) * 2015-11-17 2020-12-11 长春市福迪奥美科技有限公司 精氨酸酶组合物、精氨酸酶激活剂及其应用
CN106434710A (zh) * 2016-10-14 2017-02-22 江南大学 一种耐热精氨酸酶的基因表达序列和应用
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
TWI922426B (zh) * 2017-08-16 2026-04-21 香港商鎧耀波麗堂（香港）有限公司 用於胺基酸耗竭治療之組合物的用途
TWI878212B (zh) 2017-12-05 2025-04-01 瑞典商伊梅爾迪卡製藥公司 用於治療精胺酸酶1缺乏症之方法及組合物
CN112513099A (zh) 2018-05-31 2021-03-16 香港理工大学 用于癌症、肥胖症、代谢紊乱和相关并发症及合并症的精氨酸耗竭剂的组合物和应用
WO2020081994A1 (en) 2018-10-19 2020-04-23 Aerase, Inc. Arginine depletion therapy for treatment of gamt deficiency
CN109793917B (zh) * 2019-02-11 2020-10-09 海南建科药业有限公司 一种预防结直肠手术后吻合口瘘的凝胶的制备方法
BR112022003633A2 (pt) 2019-08-30 2022-06-07 Aeglea Biotherapeutics Inc Métodos para produção de arginase 1 recombinante humana e usos da mesma
EP4069280A4 (en) * 2019-12-02 2024-01-03 The Hong Kong Polytechnic University METHOD FOR INDUCING INTERMITTENT FASTING AND MODULATING AUTOPHAGY
TW202200210A (zh) * 2020-04-17 2022-01-01 香港商康達醫藥科技有限公司 使用精胺酸酶治療病毒感染之方法
US20230181694A1 (en) * 2020-05-14 2023-06-15 Kyon Biotech Ag Treatment of respiratory viral infections
WO2022063178A1 (en) * 2020-09-23 2022-03-31 The Hong Kong Polytechnic University Fluorescent biosensor for rapid determination of l-arginine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO2004001048A1 (en) * 2002-06-20 2003-12-31 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
WO2004000349A1 (en) * 2002-06-20 2003-12-31 Bio-Cancer Treatment International Limited Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
WO2004022004A3 (en) * 2002-09-06 2004-12-23 Bayer Pharmaceuticals Corp Modified glp-1 receptor agonists and their pharmacological methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063780A2 (en) * 2002-01-25 2003-08-07 Cancer Treatments International Therapeutic composition for treatment of cancer by arginine depletion
CN1745847A (zh) 2004-09-08 2006-03-15 康达医药科技有限公司 用精氨酸酶治疗肝炎的药物组合物和方法
WO2006058486A1 (en) 2004-12-03 2006-06-08 Bio-Cancer Treatment International Limited Use of arginase in combination with 5fu and other compounds for treatment of human malignancies
CA2766039A1 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
WO2004001048A1 (en) * 2002-06-20 2003-12-31 Bio-Cancer Treatment International Limited Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
WO2004000349A1 (en) * 2002-06-20 2003-12-31 Bio-Cancer Treatment International Limited Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation
CN1918298A (zh) * 2002-06-20 2007-02-21 康达医药科技有限公司 利用精氨酸剥夺治疗人恶性肿瘤的药物组合物及方法
WO2004022004A3 (en) * 2002-09-06 2004-12-23 Bayer Pharmaceuticals Corp Modified glp-1 receptor agonists and their pharmacological methods of use

Also Published As

Publication number Publication date
JP2012521201A (ja) 2012-09-13
AU2010242422B2 (en) 2014-12-04
JP5746137B2 (ja) 2015-07-08
US8507245B2 (en) 2013-08-13
AU2010242422A1 (en) 2011-10-27
WO2010124547A1 (en) 2010-11-04
CA2756442C (en) 2016-03-29
EP2411040A4 (en) 2012-09-12
US20100247508A1 (en) 2010-09-30
CN102481345A (zh) 2012-05-30
EP2411040B1 (en) 2015-09-23
EP2411040A1 (en) 2012-02-01
CA2756442A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
CN102481345A (zh) 精氨酸酶的定向位点聚乙二醇化及其作为抗癌和抗病毒试剂的用途
US9382525B2 (en) Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
US10724026B2 (en) Engineered primate L-methioninase for therapeutic purposes
JP2020111611A (ja) 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
CN105612252B (zh) 作为抗新生剂的工程改造的灵长类动物胱氨酸/半胱氨酸降解酶
US11168142B2 (en) Administration of kynurenine depleting enzymes for tumor therapy
JP2013518594A (ja) メチオニンγリアーゼ酵素を含む作製された酵素およびその薬理学的調製物
WO2013097658A1 (zh) 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
WO2006133276A2 (en) Methods for dissolving cystine stones and reducing cystine in urine
US20260022367A1 (en) Broad spectrum nanozymes
TWI331531B (en) Pharmaceutical preparation and method of treatment of human malignancies with arginine deprivation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: Kowloon, Hongkong, China

Patentee after: The Hong Kong Polytechnic University

Address before: China Hung Hom Kowloon Hongkong

Patentee before: The Hong Kong Polytechnic University

CP02 Change in the address of a patent holder